Back to top

Image: Bigstock

Ironwood Pharmaceuticals, Inc.

Read MoreHide Full Article

Ironwood’s third-quarter results were disappointing with the company reporting a wider-than-expected loss and revenues falling significantly short of expectations. The company is heavily dependent on Linzess for growth. Ironwood is working on expanding Linzess' label – any setback would weigh heavily on the stock considering that the rest of the pipeline is mostly mid-stage in nature. Moreover, Linzess' target market has quite a few players with other companies working on bringing new products to market. However, Linzess’ scrips improved sequentially. Additionally, Ironwood’s partnerships with big companies including Allergan among others for the development and commercialization of Linzess in different territories are also encouraging.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Ironwood Pharmaceuticals, Inc. (IRWD) - free report >>

Published in